Publication: A systematic analysis of mitochondrial aminoacyl tRNA synthetase variants in a rare disease cohort
| dc.contributor.coauthor | Ratnaike, Thiloka E. | |
| dc.contributor.coauthor | Paramonov, Ida | |
| dc.contributor.coauthor | Matalonga, Leslie | |
| dc.contributor.coauthor | Polavarapu, Kiran | |
| dc.contributor.coauthor | Olimpio, Catarina | |
| dc.contributor.coauthor | Horvath, Rita | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.kuauthor | Kule, Mehmet Eren | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.date.accessioned | 2026-01-16T08:45:33Z | |
| dc.date.available | 2026-01-16 | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are a group of proteins encoded by nuclear DNA that play a crucial role in mitochondrial protein synthesis. Mitochondrial diseases caused by mt-aaRS variants are phenotypically heterogenous but often present with significant neurological features such as childhood-onset encephalopathy and seizures. As such, these conditions are a diagnostic challenge. We present an approach that systematically quantifies phenotypic similarity of individuals with an mt-aaRS variant to published cases, to aid variant interpretation, in RD-Connect-a large Europe-wide rare disease cohort. Across 98 individuals with a mt-aaRS gene of interest, we prioritised 38 individuals with 63 variants following bioinformatic and manual analyses. We additionally reviewed Exomiser prioritisation using a pre-defined gene list for neurological disorders within the RD-Connect Genome-Phenome Analysis Platform (GPAP). We were able to generate likely diagnoses in 11 individuals and VUS findings in 13 individuals, following careful phenotype similarity analysis using a phenotype-genotype dataset generated from 234 published individuals. Four of these 24 individuals did not have an Exomiser-ranked gene variant in the GPAP. Therefore, this approach, using individual-level curated phenotype-genotype data to support variant interpretation, can highlight potentially significant variants that may not be captured by current pipelines. This workflow can be replicated in other heterogeneous rare diseases to support clinical practice. | |
| dc.description.fulltext | Yes | |
| dc.description.harvestedfrom | Manual | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | PubMed | |
| dc.description.indexedby | Scopus | |
| dc.description.openaccess | Hybrid OA | |
| dc.description.publisherscope | International | |
| dc.description.readpublish | N/A | |
| dc.description.sponsoredbyTubitakEu | N/A | |
| dc.description.sponsorship | TER was an academic clinical lecturer supported by the University of Cambridge during the project. TER is also funded as a University of Bristol clinical research fellow by the Elizabeth Blackwell Institute AI in Health Award. RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/V009346/1), the Addenbrookes Charitable Trust (G100142), the Evelyn Trust, the Stoneygate Trust, the Lily Foundation, Action for AT, the Muscular Dystrophy UK, the Rosetrees Trust (PGL23/100048), the Hereditary Neuropathy Foundation, the AFM-Telethon, the Ataxia UK, the Action for AT, the LifeArc Centre to Treat Mitochondrial Diseases (LAC-TreatMito) and the UKRI/Horizon Europe Guarantee MSCA Doctoral Network Programme (Project 101120256: MMM). She is also supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD), MR/S005021/1. This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. | |
| dc.identifier.doi | 10.1038/s41431-025-01990-y | |
| dc.identifier.eissn | 1476-5438 | |
| dc.identifier.embargo | No | |
| dc.identifier.issn | 1018-4813 | |
| dc.identifier.pubmed | 41454053 | |
| dc.identifier.quartile | Q1 | |
| dc.identifier.scopus | 2-s2.0-105026312750 | |
| dc.identifier.uri | https://doi.org/10.1038/s41431-025-01990-y | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/32019 | |
| dc.identifier.wos | 001648948300001 | |
| dc.keywords | Genomics | |
| dc.keywords | Neuromuscular disease | |
| dc.language.iso | eng | |
| dc.publisher | Springer Nature | |
| dc.relation.affiliation | Koç University | |
| dc.relation.collection | Koç University Institutional Repository | |
| dc.relation.ispartof | European Journal of Human Genetics | |
| dc.relation.openaccess | Yes | |
| dc.rights | CC BY-NC-ND (Attribution-NonCommercial-NoDerivs) | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Biochemistry and molecular biology | |
| dc.subject | Genetics and heredity | |
| dc.title | A systematic analysis of mitochondrial aminoacyl tRNA synthetase variants in a rare disease cohort | |
| dc.type | Journal Article | |
| dspace.entity.type | Publication | |
| person.familyName | Kule | |
| person.givenName | Mehmet Eren | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
